Neal Kleiman, MD — The Methodist Hospital, Baylor College of Medicine and / George D. Dangas, MD, PhD — Columbia University Medical
Faculty Disclosure
Dr. Kleinman:
- Grant and/or Research Support: Millennium Therapeutics; The Medicines Company
- Consultant: Sanofi-Aventis
Dr. Dangas:
Nothing to Disclose
Learning Objectives
- Name the clinical characteristics of HIT
- List the different types and uses of direct thrombin inhibitors
- Provide an overview of clinical trials of heparin-induced thrombocytopenia
- List the various types of coronary interventions in patients with HIT